Jonathan J. Hodgins

1.2k total citations · 1 hit paper
7 papers, 803 citations indexed

About

Jonathan J. Hodgins is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Jonathan J. Hodgins has authored 7 papers receiving a total of 803 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Immunology and 2 papers in Genetics. Recurrent topics in Jonathan J. Hodgins's work include CAR-T cell therapy research (4 papers), Virus-based gene therapy research (2 papers) and Cell Adhesion Molecules Research (2 papers). Jonathan J. Hodgins is often cited by papers focused on CAR-T cell therapy research (4 papers), Virus-based gene therapy research (2 papers) and Cell Adhesion Molecules Research (2 papers). Jonathan J. Hodgins collaborates with scholars based in Canada, United States and France. Jonathan J. Hodgins's co-authors include Michele Ardolino, Rebecca C. Auer, John C. Bell, S. Khan, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Alexandre Iannello, Michael W. McBurney, David H. Raulet and Joy Hsu and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Jonathan J. Hodgins

7 papers receiving 793 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

2018 609 citations Joy Hsu, Jonathan J. Hodgins et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Jonathan J. Hodgins

Since Specialization

Citations

This map shows the geographic impact of Jonathan J. Hodgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan J. Hodgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan J. Hodgins more than expected).

Fields of papers citing papers by Jonathan J. Hodgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan J. Hodgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan J. Hodgins. The network helps show where Jonathan J. Hodgins may publish in the future.

Co-authorship network of co-authors of Jonathan J. Hodgins

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan J. Hodgins. A scholar is included among the top collaborators of Jonathan J. Hodgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan J. Hodgins. Jonathan J. Hodgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses 2023 ·Cells ·(unknown), Jonathan J. Hodgins, (unknown), Barbara C. Vanderhyden, Michele Ardolino, Luc A. Sabourin	2
2	CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness 2022 ·iScience ·(unknown), Jonathan J. Hodgins, Christiano Tanese de Souza, (unknown), (unknown), Marie Marotel, (unknown), (unknown), (unknown), Rebecca C. Auer, Michele Ardolino, Luc A. Sabourin	13
3	853 ACTM-838: a microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs after IV dosing in T-cell excluded solid tumors 2021 ·SHILAP Revista de lepidopterología ·(unknown), Alexandre Iannello, Keith Cheung, (unknown), Marie Marotel, (unknown), (unknown), Jonathan J. Hodgins, Michele Ardolino, (unknown), Christopher G. Thanos, Laura Hix Glickman	1
4	Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers 2020 ·Oncogene ·Khalid N. Al‐Zahrani, (unknown), David P. Cook, (unknown), Jonathan J. Hodgins, (unknown), (unknown), Christiano Tanese de Souza, John C. Bell, Rebecca C. Auer, Michele Ardolino, Barbara C. Vanderhyden, Luc A. Sabourin	10
5	Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice 2020 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·(unknown), (unknown), Dounia Hamoudi, (unknown), Khalid N. Al‐Zahrani, Jonathan J. Hodgins, (unknown), (unknown), (unknown), Jérôme Frenette, Michele Ardolino, Joe N. Kornegay, Luc A. Sabourin	5
6	Killers 2.0: NK cell therapies at the forefront of cancer control 2019 ·Journal of Clinical Investigation ·Jonathan J. Hodgins, S. Khan, (unknown), Rebecca C. Auer, Michele Ardolino	163
7	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade breakdown → 2018 ·Journal of Clinical Investigation ·Joy Hsu, Jonathan J. Hodgins, (unknown), (unknown), Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, (unknown), Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, (unknown), Karen Jardine, (unknown), John C. Bell, Michael W. McBurney, David H. Raulet, Michele Ardolino	609

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact